ClinicalTrials.gg
CompletedNCT06937034H25-878 ORCHESUpdated Nov 17, 2026

Study on Practical ExperienceS of Treatment With Foslevodopa/foScaRbidopa in Advanced Parkinson's Disease

An observational study in Parkinson's Disease, sponsored by AbbVie. Completed at 5 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by AbbVie · Observational

How we know

Updated Nov 17, 2026Now CompletedFirst site in Germany+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
2,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Parkinson Disease by AbbVie — 5 open to participants now, 8 under way, none of them phase 3. Parkinson Disease · AbbVie.

Enrollment
Largest of 18
2,000 · median 131
Started
2025
with 3 others
Observational
18 of 44
5 open now
Registered
39th of 44
by date

Among the 44 studies in Parkinson Disease by AbbVie, this one has the largest enrollment of the 18 observational ones that give a count, is one of 4 that started in 2025, is one of 18 observational ones, and was the 39th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

5 of the 44 studies in Parkinson Disease by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Parkinson Disease by AbbVie, or all of them as a file.
02

Study summary

Main objective of this study is to describe the evolution of infusion settings (base, high and low infusion rates) of foslevodopa/foscarbidopa subcutaneous infusion (LDp/CDp) at different timepoints in the treatment of advanced Parkinson's disease (aPD) as captured in ONE-CRM.

03

Conditions studied

  • Parkinson's Disease

Browse trials for

Keywords

  • Parkinson's Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Advanced Parkinson Disease Patients treated with foslevodopa/foscarbidopa.

Eligibility criteria

Inclusion Criteria:

- Diagnosed with levodopa-responsive idiopathic Parkinson's Disease prescribed on LDp/CDp CSCI in routine clinical practice who have consented to be enrolled in the AbbVie Patient Support Program.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
2,000 participants (actual)
Patient registry
No

Groups and cohorts

  • Participants with Parkinson's Disease

    Advanced Parkinson Disease Patients treated with foslevodopa/foscarbidopa.

06

What researchers measure

Primary outcomes

  1. Mean Base Infusion Rate

    Mean base infusion rate (ml/hour) will be assessed

    Time frame: Through end of optimization period (defined as no additional dose modification for at least 15 days since the last dose modification).

  2. Mean Low Infusion Rate

    Mean low infusion rate (ml/hour) will be assessed

    Time frame: Through end of optimization period (defined as no additional dose modification for at least 15 days since the last dose modification).

  3. Mean High Infusion Rate

    Mean high infusion rate (ml/hour) will be assessed

    Time frame: Through end of optimization period (defined as no additional dose modification for at least 15 days since the last dose modification).

07

Study locations

5 sites
08

References and documents

Publications

  • Warnecke T, Van der Plas AA, Schwingenschuh P, Johansson A, Simu M, O'Meara M, Gupta R, Fritz B, Bergmann L, Parra JC, Sudmeyer M. Observational Retrospective Cohort of Patient Support Program Data on Practical Experiences of Treatment with Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease: The ORCHESTRA Study. Neurol Ther. 2026 Aug;15(4):2073-2095. doi: 10.1007/s40120-026-00978-0. Epub 2026 Jun 20. PubMed 42322391 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Apr 2025 to primary completion in Jul 2025, 3 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Dec 2025 → Jul 2025 and completion Dec 2025 → Jul 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2025
First posted
Apr 20, 2025
StartActual
Apr 14, 2025
Primary completionActual
Jul 28, 2025was Dec 2025
CompletionActual
Jul 28, 2025was Dec 2025
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 17, 2026
Sites
2 sites added, 1 site removed — first site in Germany
Show 2 added (1 Germany, 1 Romania)
  • Universitaetsklinikum Muenster - Von-Esmarch-Strasse /ID# 279025 · Münster, Germany
  • Universitatea De Medicina Si Farmacie Victor Babes /ID# 276720 · Timișoara, Romania
Show 1 removed
  • Universitatea De Medicină Și Farmacie Victor Babeș /ID# 276720 · Timișoara, Romania
Nov 17, 2026
Primary completion
Dec 2025→Jul 28, 2025 (actual)
Nov 17, 2026
Study completion
Dec 2025→Jul 28, 2025 (actual)
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Recruiting→Completed
    2 sites added, 1 site removed — first site in Germany
    Show 2 added (1 Germany, 1 Romania)
    • Universitaetsklinikum Muenster - Von-Esmarch-Strasse /ID# 279025 · Münster, Germany
    • Universitatea De Medicina Si Farmacie Victor Babes /ID# 276720 · Timișoara, Romania
    Show 1 removed
    • Universitatea De Medicină Și Farmacie Victor Babeș /ID# 276720 · Timișoara, Romania
    Primary completion Dec 2025→Jul 28, 2025 (now actual)
    Study completion Dec 2025→Jul 28, 2025 (now actual)
    + 5 other changes: identifiers, verification date, design details, contact details and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06937034
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Apr 20, 2025
Start date
Apr 14, 2025
Primary completion
Jul 28, 2025
Completion
Jul 28, 2025
Last update
Nov 17, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion